Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
- Amstutz U University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland.
- Henricks LM Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Offer SM Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
- Barbarino J Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
- Schellens JHM Department of Clinical Pharmacology, Division of Medical Oncology and Division of Pharmacology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Swen JJ Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, the Netherlands.
- Klein TE Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
- McLeod HL DeBartolo Family Personalized Medicine Institute and the Department of Population Sciences, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA.
- Caudle KE Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Diasio RB Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
- Schwab M Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
- 2017-11-21
Published in:
- Clinical pharmacology and therapeutics. - 2018
Antimetabolites, Antineoplastic
Capecitabine
Clinical Decision-Making
Dihydrouracil Dehydrogenase (NADP)
Drug Dosage Calculations
Fluorouracil
Genotype
Humans
Patient Selection
Pharmacogenetics
Pharmacogenomic Testing
Pharmacogenomic Variants
Phenotype
Precision Medicine
Predictive Value of Tests
English
The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1002/cpt.911
- PMID 29152729
- Persistent URL
- https://folia.unifr.ch/global/documents/186695
Statistics
Document views: 9
File downloads:
- fulltext.pdf: 0